Do Combination Therapies Hold Hope for Prostate Cancer Patients?
A phase 1 trial shows promise in treating metastatic prostate cancer with a single priming dose of radioligand therapy and immunotherapy.
University of California San Francisco
Give to UCSF
Why Progress in Alzheimer’s Disease Treatment Has Taken 30 Years
UCSF's Adam Boxer, MD, PhD, and Harvard neurologist Reisa Sperling, MD, review the history of clinical trials over the past 30 years in Alzheimer’s research with what was learned and how new biomarkers and clinical trial approaches are being used to find more effective treatments in a more efficient way than in the past.
New Care Model Delivers Hepatitis C Treatment to Most Vulnerable
UCSF researchers developed a new neighborhood-based model of care that brings medicine to people immediately after being diagnosed with hepatitis C.
Breakthrough Drug Helps Children with New-Onset Type 1 Diabetes
A study found that children who were recently diagnosed with type 1 diabetes need less supplemental insulin to keep their blood sugar in a healthy range if they use the immunotherapy drug teplizumab.
Neuroscientists to Reveal New Insights into Alzheimer's
UCSF experts to discuss amyloid therapies and dementia research at CTAD conference, addressing equity, novel treatments, and innovative studies.
$151M Grant Will Drive New Era in Alzheimer’s Treatments
A new study will combine an Alzheimer’s medication that slows disease progression in some patients with two other drugs to see if their effects can be amplified.
Brief Dialysis May Be Best for Some Kidney Patients
Patients of acute kidney injury might not need as much dialysis as patients with end-stage kidney disease, and might benefit more from weaning off dialysis to avoid risk for heart disease, infection, organ damage and death.
Can a Simple Fentanyl Test Curb San Francisco’s Overdose Crisis?
With fentanyl overdose deaths at an all-time high, a successful UCSF-funded pilot project to distribute fentanyl test strips is being expanded by California Gov. Gavin Newsome as part of his plan to address the crisis.
UCSF Research Vital to First Drug for Deadly Bone Disease
FDA approves palovarotene (Sohonos) for rare FOP, reducing HO by 54%. Significant step in improving lives of affected patients.
Will a Pill Help New Moms Bounce Back from Postpartum Depression?
Zuranolone (Zurzuvae), the first pill for patients suffering from postpartum depression, is expected to be available by the end of 2023. Though it may relieve depressive symptoms, it has some drawbacks such as sedation and dangers in breastfeeding.
MDMA’s Latest Trial Results Offer Hope for Patients with PTSD
A clinical trial showed that MDMA, the so-called psychedelic drug also known as "ecstasy" or "molly," can be a powerful new tool in treating people with moderate-to-severe PTSD.
Are the Newest Weight Loss Drugs Too Good to be True?
Three injectable medications, Wegovy, Ozempic and Mounjaro, are often taken as weight management drugs. UCSF health experts weigh in on the benefits and risks of taking the medications for obesity.
Can What Works to Treat Cancer Work for Diabetes?
UCSF researchers are working across disease specialties. Diabetes researchers are looking at how oncologists use CAR T-cell therapy to reprogram a person’s immune system to attack cancer cells, for example. They hope to similarly reprogram the immune system to fight diabetes.
Looking to Cut Back on Wine and Beer? This Pill Might Help
People looking to cut back on binge drinking alcohol can take a single pill of naltrexone right before drinking to curb consumption.
Commentary: New Class of Drugs Shifts Momentum on Alzheimer’s
A new Alzheimer’s drug is expected to be approved by the Food and Drug Administration (FDA). However, the medication works best mostly for those in the earliest stages of Alzheimer’s.
